Nivolumab 40 mg Side Effects
Nivolumab at any dose, including 40 mg, causes immune-related adverse events (irAEs) in 74-85% of patients, with 12-20% experiencing severe (grade 3-4) toxicities. 1
Most Common Side Effects
The adverse event profile for nivolumab is consistent across dosing regimens, with the most frequently reported effects being:
General Symptoms
- Fatigue (16-37% of patients) - the single most common adverse event with anti-PD-1 therapy 1
- Pyrexia/fever
- Edema
Skin and Subcutaneous Reactions
- Rash (35% any grade, <1% grade 3-4) 2
- Pruritus (28% any grade, <1% grade 3-4) 2
- Maculopapular rash
- Vitiligo
Gastrointestinal Effects
- Diarrhea (37% any grade, 2.4% grade 3-4) 2
- Nausea (23%)
- Colitis (1% grade 3-4 with monotherapy) 2
- Abdominal pain
- Constipation
Musculoskeletal
- Musculoskeletal pain (32%) 2
- Arthralgia (19%)
- Myalgia
Respiratory
- Cough (19%)
- Dyspnea (10%)
Endocrine Disorders
- Hypothyroidism (12%) 2
- Hyperthyroidism
- Hypophysitis (<1% grade 3-4)
- Adrenal insufficiency
Serious but Less Common Immune-Related Adverse Events
Any organ system can be affected by irAEs, though certain life-threatening toxicities require immediate recognition: 1
High-Risk Toxicities (Potentially Fatal)
- Pneumonitis (<1% with monotherapy but potentially lethal) 2
- Myocarditis (rare but life-threatening) 1, 2
- Neurological disorders including encephalitis 1
- Severe colitis (can progress to perforation)
Hepatic Toxicity
- Elevated ALT (25% any grade, 1.8% grade 3-4) 2
- Elevated AST (24% any grade, 1.3% grade 3-4) 2
- Hepatitis (3% in adjuvant setting) 2
Pancreatic Toxicity
- Elevated lipase (25% any grade, 7% grade 3-4) 2
- Elevated amylase (17% any grade, 3.3% grade 3-4) 2
- Pancreatitis
Renal Toxicity
- Nephritis
- Increased creatinine (12% any grade) 2
Laboratory Abnormalities
Common laboratory changes include: 2, 3
- Lymphopenia (27% any grade, 0.4% grade 3-4)
- Anemia (26% any grade)
- Leukopenia (14%)
- Neutropenia (13%)
- Hyponatremia (16% any grade, 1.1% grade 3-4)
- Hyperkalemia (12%)
- Hypocalcemia (10%)
Timing of Adverse Events
irAEs typically occur within the first 8-12 weeks of treatment initiation, though onset can be delayed up to 1 year after discontinuation. 1 Skin toxicities often develop first, followed by gastrointestinal and endocrine effects. 1
Dose-Specific Considerations for 40 mg
Recent evidence suggests that nivolumab 40 mg (low-dose) demonstrates comparable safety to standard dosing (3 mg/kg or 240-480 mg). 4 In a matched cohort study with 5-year follow-up:
- Any adverse events: 69% (40 mg) vs 77% (standard dose)
- Grade 3-4 adverse events: 6% (40 mg) vs 13% (standard dose)
- No statistically significant difference in toxicity profiles 4
The 40 mg dose appears to maintain the same spectrum of adverse events as higher doses, but potentially with reduced severity. 4, 5
Critical Management Principles
Grade 1 toxicities: Continue treatment with close monitoring 6
Grade 2 toxicities: Hold therapy for worrisome symptoms (diarrhea, arthritis, dyspnea, hepatitis) or multiple concurrent grade 2 events 7
Grade 3-4 toxicities: Permanently discontinue nivolumab and initiate high-dose corticosteroids (except for endocrinopathies stable on replacement therapy), tapering over 4-6 weeks 7, 6
Common Pitfalls
- Fatigue is often attributed to hypothyroidism but only a minority of cases are thyroid-related - evaluate comprehensively 1
- Pneumonitis can be subtle initially - maintain high index of suspicion with any respiratory symptoms 2
- irAEs can occur long after treatment discontinuation - surveillance must continue beyond active therapy 1
- Colitis risk may differ between dosing schedules - 240 mg Q2W showed higher colitis incidence than 480 mg Q4W in some analyses 8